 (Heart 1996;75:455-462) 
11*7 (SD 2.7) v 15-1 (5.2) mllkg/min, P = 0.02) and cardiac output (3.97 (1.03) v 4 79 (1.06) litres/min, P = 0.04) were found to be independent prognostic risk factors. Peak Vo2 and cardiac index (CI) were then analysed in the last 141 consecutive patients accepted for cardiac transplantation. All deaths and 88% of the deteriorations to status 1 on the waiting list occurred in patients with either a CI < 2*0 or a Vo, < 12. In those with a CI < 2-0 and a Vo, < 12, 38% died or deteriorated to status 1 in the first year on the waiting list. Patients with CI >i 2*0 and a V02 > 12 all survived throughout follow up. Using a Cox's proportional hazards model with CI and peak Vo, as covariates, tables were constructed predicting the chance of surviving for (a) 60 days and (b) 1 year on the waiting list. Conclusions-These data provide a basis for risk stratification of status 2 patients on the heart transplant waiting list.
(Heart 1996;75:455-462) Keywords: heart failure; prognosis; heart transplantation Waiting lists for heart transplants are increasing in centres throughout the USA and in many other countries,' 2 the average length of time patients wait before undergoing transplantation is increasing, and the ratio of patients dying on the waiting list to patients being transplanted has risen from 0 07 in 1983 to 0-21 in 1989. 3 Within the waiting list population the group that suffers most from the worsening imbalance between the demand for transplants and the supply of donor organs is the patients in status 2 (patients not requiring inotropic or mechanical circulatory support) who in most centres are transplanted in the chronological order in which they are accepted on to the waiting list. Patients who present in status 1 (requiring inotropic or mechanical circulatory support) or who deteriorate from status 2 to status 1, are transplanted ahead of status 2 patients because of their high mortality if they remain on the waiting list on circulatory support. Selecting status 1 patients for urgent transplantation has been shown to be an appropriate use of donor organs in terms of the impact on overall mortality,4 but has resulted in a high percentage of donor organs that become available going to these severely ill patients, with fewer organs remaining for implantation into status 2 patients.
In this study we examined the mortality in all patients on the waiting list for heart transplant over an eight year period in order to define the length of time that patients who died had been waiting and to determine how many of the deaths occurred in patients who had progressed from status 2 to status 1. We also compared two groups from within the status 2 patients on the waiting list who were at opposite ends of the spectrum for prognostic risk: those who died on the waiting list; and those who survived for more than one year on the waiting list without adverse outcome. By using this approach it was possible to identify clinical variables that were independent prognostic indicators and to propose a strategy to improve our ability to target the available donor organs for transplant not only to status 1 patients, but also to status 2 patients with a high risk of death on the waiting list. The policy suggested has the potential to decrease overall mortality in patients referred for heart transplant and to avoid performing heart transplants on patients who are unlikely to gain survival benefit from the procedure.
Methods
The study was a retrospective review of the clinical records of patients aged 18 years or older who were placed on the Stanford University Hospital heart transplant waiting list between 1 June 1986 and 31 May 1994. Patients who were accepted for repeat heart transplants were excluded from the study. Data drawn from the pretransplant evaluation database were supplemented from the clinical files which are kept for each patient referred for heart transplantation. In instances where the clinical variables to be assessed were incomplete in these files, the inpatient hospital medical records were reviewed.
In the first phase of the study data were used to define the two patient groups: status 2 patients who died on the waiting list; and status 2 patients who survived for more than one year on the waiting list without adverse outcome. Accepted outcomes in the latter group were: heart transplantation; removal from the waiting list because of clinical improvement; or continued listing for transplantation at the end of the study period without deterioration to status 1 Total number of deaths = 32 the status 2 deaths (66%) were sudden cardiac deaths. Table 2 shows a comparison of the clinical variables measured in status 2 patients who died on the waiting list (n = 32) compared with those of status 2 patients who survived for more than one year on the waiting list without an adverse outcome (n = 52). With univariate analysis using a two tailed Mann Whitney U test there were four variables that showed a significant difference between the two groups: systolic blood pressure, cardiac output, peak oxygen consumption, and serum sodium. Differences in other variables such as ejection fraction, pulmonary capillary wedge pressure (PCWP) and pulmonary vascular resistance (PVR) did not reach significance. The two groups were closely matched for age (51-3 (9 0) in those who died, 51-2 (9 2) in those who survived). In addition to these variables we compared: gender, aetiology of heart failure, arrhythmic history, and ACE inhibitor treatment. Patients were predominantly male in both groups (88% of those who died, 96% of those who survived, NS), ischaemic heart disease was the commonest diagnosis in each group (63% v 65%, NS) with the next commonest aetiology being idiopathic dilated cardiomyopathy (28% v 25%, NS). There was also no significant difference in the frequency of a history of arrhythmia (59% in patients who died, v 49% in those who survived, NS) or in the proportion of patients receiving ACE inhibitor treatment (86% in patients who died, v 88% in those who survived, NS).
Univariate analysis

MULTIVARIATE ANALYSIS
Multivariate analysis of systolic blood pressure, cardiac output, peak oxygen consumption, and serum sodium revealed that only cardiac output (P = 0-023 by logistic regression analysis) and peak Vo, (P = 0'012 by logistic regression analysis) were independently associated with adverse outcome, whether tested by a least squares or stepwise logistic regression analysis.
Because three of the status 2 patients who died while on the waiting list survived for more than one year on the list before death, data were also analysed excluding these three patients. There was no significant change in the results when these three patients were excluded. SURVIVAL Values for cardiac index and peak Vo, at the time of acceptance were collected for all patients initially in status 2 (n = 1 14 patients).
Cardiac index measurements were present for 100% of the patients accepted, and peak Vo2 had been assessed at the time of acceptance in 94 (82%). Cardiac index measurements ranged from 1P15 to 3-86 (mean 2-1 (0 56)) litres/min/m2, and peak Vo2 from 5-7 to 23-9 (mean 13-6 (3-8)) ml/kg/min. There were nine patients with cardiac index greater than or equal to 3 litres/min/m2 and eight with peak Vo2max > 20 ml/kg/min. We found that status 2 patients with a CI > 2 litres/min/m2 at the time of acceptance had a one year survival free from death or deterioration to status 1 of 83%.
Status 2 patients with Vo2 > 12 ml/kg/ min had a one year survival free from death or deterioration to status 1 of 82%. In both cases survival above and below the dichotomisation points were highly significantly different (fig 3) . Neither variable on its own identified all of those who died while on the waiting list. We therefore tried two strategies based on these dichotomisation points: (1) selecting a group in which cardiac index was less than 2-0 litres/ min/m2 and peak Vo2 was less than 12 ml/kg/ min, and (2) selecting patients in whom cardiac index was > 2'0 1/min/m2 and peak Vo2 was > 12 ml/kg/min. The intention of the first strategy was to attempt to define high risk patients to be given priority. The intention of the second strategy was to identify patients with a good prognosis in whom transplantation could be deferred, allowing resources to be concentrated on higher risk patients. The percentage of patients identified by these two different strategies is shown in Although values of 10,9 11,8 12,7 14,6 and 2010 have all been proposed as useful dichotomisation points to identify high or low risk subsets, the value most widely accepted derives from the observation by ourselves5 and by Mancini et a?6 that patients with peak Vo2 greater than 14 ml/kg/min were a relatively good prognosis group in whom heart transplantation could be deferred. In the Task Force 3 report, a Vo2 less than 14 ml/kg/min is given as a probable indication for heart transplantation, although the report did not go so far as to include this figure in its recommendations. The use of the policy suggested by Mancini et al of deferring transplantation in patients with Vo2 greater than 14 ml/kg/min would have excluded 33% of the status 2 patients from the waiting list (slightly less than the 39% excluded by the application of cardiac index > 2-0 litres/min/m2 and peak Vo2 > 12 ml/kg/min in our study); however 15% of all deaths in the status 2 patients occurred in patients with Vo2 greater than 14. Furthermore these deaths all occurred within two months from the time of acceptance; the three monthly reassessment of peak Vo2 advised in conjunction with this policy would therefore not have helped these patients. Using the strategy of cardiac index > 2'0 litres/min/m2 and peak Vo2 > 12 ml/kg/min, there were no deaths during follow up in patients satisfying both criteria. While cardiac output has been identified as an independent prognostic indicator in at least one other study,'1 several other variables such as low serum sodium, raised pulmonary artery diastolic pressure, left ventricular end diastolic dilatation, permanent pacing,8 aetiology, New York Heart Association class, third heart sound, pulmonary wedge pressure, and mean systemic blood pressurell have also been found to be independent risk factors for death in patients either accepted or referred for heart transplantation. Some of these variables were significant univariate predictors of death in our series, but only peak Vo2 and cardiac index were indepen-460 group.bmj.com on June 25, 2017 -Published by http://heart.bmj.com/ Downloaded from Inalysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria dently significant on multivariate analysis. Another study of prognosis in patients evaluated, but not necessarily accepted, for heart transplantation did not find cardiac index to be a useful prognostic indicator. ' It has been suggested that patients who have survived on the waiting list for over nine months do not to derive survival benefit from transplantation,'3 and it has been proposed that patients who have survived on the list for this time should be removed from the waiting list.2 It is clearly preferable, however, to exclude patients who will not gain survival benefit from transplantation at the time of evaluation, rather than after nine months on the list. While reduction of the current candidate pool may be facilitated by such a removal policy, it may be difficult for patients to feel confidence in a decision removing them after they have been on the waiting list for nine months. There is also a risk in centres with small waiting lists and few patients with less common blood groups that chance fluctuations in the availability of hearts of a particular blood group may result in patients with a good medium term outlook being transplanted inappropriately within the nine month period. Survival probability tables of the type presented here provide an alternative approach to the management of such patients who are borderline for placement on the heart transplant waiting list.
The anticipated reduction in status 2 patients of 39% using the cardiac index > 2-0 1/min/m2 and peak Vo2 > 12 ml/kg/min criteria (or a similar reduction using a one year death and deterioration survival function of 075) also compares favourably with the age restriction to an upper limit of 55 years which it has been suggested would achieve a 30% reduction in the waiting list2 and would avoid excluding patients on the grounds of age who have been found to have results from transplantation comparable to those of younger patients. ' Reducing the size of the status 2 waiting list by avoiding accepting patients who are unlikely to gain survival benefit from transplantation will tend to reduce the time to transplantation for the higher risk status 2 patients who remain on the waiting list. However, it is unlikely that this measure alone will be sufficient to reduce the waiting time to within two months from the time of acceptance. In our patient population, the majority of status 2 patients who died on the waiting list did so within two months from the time of acceptance for transplantation. Conversely, status 2 patients with cardiac index < 2-0 litres/min/m2 and peak Vo, < 12 ml/kg/min had a very poor prognosis on the waiting list. Using tables of the type constructed here from a Cox proportional hazards model, it may be possible to predict risk of death or deterioration to status 1 from measurements of cardiac index and peak Vo2 in individual patients. This approach could be used to specify patients for whom it would be appropriate either to avoid transplantation and continue with medical treatment, or to consider early transplantation or entry into trials of new treatments. These criteria should be tested retrospectively on waiting list data bases in other populations and could form the basis for a prospective multicentre randomised trial designed to assess the value of the strategy described in the management of status 2 patients being listed for heart transplantation.
